SymBio Pharmaceuticals Limited (4582.T)
JPY 212.0
(-1.85%)
JPY 212.0
(-1.85%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.58 Billion | 10 Billion | 8.25 Billion | 2.98 Billion | 2.83 Billion | 3.83 Billion |
| Cost of Revenue | 1.17 Billion | 2.4 Billion | 2.45 Billion | 2.12 Billion | 1.97 Billion | 2.66 Billion |
| Gross Profit | 4.41 Billion | 7.59 Billion | 5.8 Billion | 866.85 Million | 864.75 Million | 1.17 Billion |
| Operating Expenses | 5.22 Billion | 5.63 Billion | 4.78 Billion | 5.37 Billion | 5.16 Billion | 3.82 Billion |
| Selling, General and Administrative Expenses | 2.58 Billion | 3.08 Billion | 2.97 Billion | 3.06 Billion | 5.16 Billion | 3.82 Billion |
| Research and Development Expenses | 2.63 Billion | 2.55 Billion | 1.73 Billion | 2.26 Billion | 2.44 Billion | 1.83 Billion |
| Other Expenses | - | 5.63 Billion | 4.78 Billion | 5.37 Billion | -10.68 Million | -11.04 Million |
| Cost and Expenses | 6.4 Billion | 8.04 Billion | 7.23 Billion | 7.49 Billion | 7.13 Billion | 6.49 Billion |
| Operating Income | -811.66 Million | 1.96 Billion | 1.01 Billion | -4.5 Billion | -4.3 Billion | -2.65 Billion |
| Interest Expense | 11.47 Million | 45.86 Million | 1.88 Million | 26.9 Million | 13.85 Million | 29.53 Million |
| Income Tax Expense | 767.42 Million | 927.04 Million | -1.03 Billion | 3.8 Million | 3.8 Million | 3.8 Million |
| Earnings before Tax | -1.19 Billion | 2.1 Billion | 1 Billion | -4.08 Billion | -4.37 Billion | -2.74 Billion |
| Net Income | -1.96 Billion | 1.17 Billion | 2.03 Billion | -4.09 Billion | -4.37 Billion | -2.75 Billion |
| Earnings Per Share Basic | -49.19 | 30.20 | 53.04 | -124.13 | -189.03 | -165.54 |
| Earnings Per Share Diluted | -49.19 | 29.77 | 52.32 | -124.13 | -189.03 | -165.54 |
| Weighted Average Shares Outstanding | 39.9 Million | 39.04 Million | 38.31 Million | 32.95 Million | 23.15 Million | 16.62 Million |
| Weighted Average Shares Outstanding (Diluted) | 39.9 Million | 39.6 Million | 38.84 Million | 32.95 Million | 23.15 Million | 16.62 Million |
| Gross Margin | 0.79 | 0.76 | 0.70 | 0.29 | 0.30 | 0.31 |
| EBIT Margin | -0.13 | 0.20 | 0.13 | -1.66 | -1.50 | -0.68 |
| Profit Margin | -0.35 | 0.12 | 0.25 | -1.37 | -1.54 | -0.72 |
| EBITDA | -714 Million | 2.2 Billion | 1.1 Billion | -4.44 Billion | -4.26 Billion | -2.62 Billion |
| Earnings Before Tax Margin | -0.15 | 0.20 | 0.12 | -1.51 | -1.52 | -0.69 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 613.94 Million | 686.56 Million | 597.86 Million | 1.16 Billion | 5.58 Billion | 1.24 Billion |
| Cost of Revenue | 165.87 Million | 161.39 Million | 126.76 Million | 233.83 Million | 1.17 Billion | 239.3 Million |
| Gross Profit | 448.06 Million | 525.16 Million | 471.1 Million | 934.76 Million | 4.41 Billion | 1 Billion |
| Operating Expenses | 1.51 Billion | 1.43 Billion | 1.27 Billion | 1.46 Billion | 5.22 Billion | 1.23 Billion |
| Selling, General and Administrative Expenses | 558.68 Million | 597.52 Million | 586.39 Million | 648.62 Million | - | 616.97 Million |
| Research and Development Expenses | 960.93 Million | 840.42 Million | 691.41 Million | 814.6 Million | - | 619.63 Million |
| Other Expenses | - | -4.5 Million | -2.28 Million | -2.38 Million | -34.19 Million | -24.62 Million |
| Cost and Expenses | 1.68 Billion | 1.59 Billion | 1.4 Billion | 1.69 Billion | 6.4 Billion | 1.47 Billion |
| Operating Income | -1.07 Billion | -912.78 Million | -806.7 Million | -528.46 Million | -811.66 Million | -233.47 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 4.81 Million | 14.28 Million | 950 Thousand | 109.3 Million | 767.42 Million | 414.43 Million |
| Earnings before Tax | -1.29 Billion | -749.66 Million | -776.44 Million | -1.06 Billion | -1.19 Billion | -294.42 Million |
| Net Income | -1.3 Billion | -763.94 Million | -777.39 Million | -1.17 Billion | -1.96 Billion | -708.86 Million |
| Earnings Per Share Basic | -28.45 | -16.67 | -18.03 | -28.90 | - | -17.83 |
| Earnings Per Share Diluted | -28.45 | -16.67 | -18.03 | -28.90 | - | -17.83 |
| Weighted Average Shares Outstanding | 45.82 Million | 45.81 Million | 43.11 Million | 40.62 Million | 39.9 Million | 39.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 45.82 Million | 45.81 Million | 43.11 Million | 40.62 Million | 39.9 Million | 39.75 Million |
| Gross Margin | 0.73 | 0.76 | 0.79 | 0.80 | 0.79 | 0.81 |
| EBIT Margin | -2.12 | -1.34 | -1.35 | -0.43 | - | -0.13 |
| Profit Margin | -2.12 | -1.11 | -1.30 | -1.00 | -0.35 | -0.57 |
| EBITDA | -1.29 Billion | -917.22 Million | -806.7 Million | -504.62 Million | - | -162.37 Million |
| Earnings Before Tax Margin | -1.75 | -1.33 | -1.35 | -0.45 | -0.15 | -0.19 |
0002
6330
COMPINFO
RBX
TARSF
AMCX